Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. (7th April 2016)

• Record Type: Journal Article
• Authors: Nishtala, P. S.; Castelino, R. L.; Peterson, G. M.; Hannan, P. J.; Salahudeen, M. S.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 41:Number 3(2016:Jun.)
• Page Start: 279
• Page End: 284
• Publication Date: 2016-04-07
• Subjects: aged care -- antithrombotic -- antithrombotic therapy -- atrial fibrillation -- drug utilization -- elderly -- fibrinolytic agents -- medication review -- older people -- residential care; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12385
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Antithrombotics reduce the risk of stroke in individuals with atrial fibrillation (AF). However, optimal prescribing of antithrombotics in older people remains a challenge. The objective of this study was to assess the risk of stroke for aged care home residents with AF and to examine the pharmacist‐led medication reviews on the utilization of antithrombotic therapy. Methods: This retrospective study included a random sample of de‐identified residential medication management reviews (RMMRs) conducted by accredited pharmacists in aged care homes in Sydney, Australia, between August 2011 and December 2012. The study participants were 146 residents aged 65 years and older with AF living in low‐ and high‐care residential aged care facilities. Antithrombotic therapy was examined among the residents, before and after medication review. CHADS2, CHA2 DS2 ‐VASc, and HEMORR2 HAGES scoring tools were used to assess the risk of stroke and bleeding and indicate the appropriateness of antithrombotic therapy. Results and discussion: The mean age (±SD) of individuals was 88·4 (7·5) years, and 63·7% ( n = 93) were female. The majority of residents ( n = 99, 67·8%) were aged between 85 and 99 years. The mean (±SD) CHADS2 score was 3·1 (1·1), CHA2 DS2 ‐VASc was 4·6 (1·5), and HEMORR2 HAGES was 2·3 (1·0). All residents were classified as being at high risk of developing stroke. A total of 115 of 146 (78·8%) residents with AF were prescribed antithrombotics. There was a relatively low usage of anticoagulation (28·1%), and few recommendations from the medication review pharmacists to alter the thromboprophylactic therapy in AF. Application of the CHA2 DS2 ‐VASc risk tool indicated that 146 residents were eligible for antithrombotic treatments; of these, 74 (50·7%) were prescribed antiplatelets and 41 (28·1%) were prescribed anticoagulants. Of the 31 (21·2%) residents with AF were not prescribed antithrombotics, 21 (67·7%) had relative contraindications for anticoagulant treatments. What is new and conclusion: Although there was a high overall use of antithrombotic agents, the study found a reluctance to prescribe or recommend anticoagulants in eligible older people with AF, potentially due to associated contraindications and multimorbidity. The use of guideline‐recommended stroke risk tools could assist medication review pharmacists in optimizing antithrombotic therapy in older adults with AF. Abstract : The study assessed the risk of stroke for aged care home residents with atrial fibrillation (AF) and examined Residential Medication Management (RMMR) reviews on the utilization of antithrombotic therapy. This study found anticoagulants were underutilized in eligible older people with AF. Guideline‐recommended stroke scoring systems, in combination with bleeding risk assessment, may assist RMMR service providers in determining the net clinical benefit of antithrombotic therapy in older adults with AF.